Lenoir, NC – According to filings with the U.S. Securities and Exchange Commission, Exela Pharma Sciences is raising $26,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Phanesh Koneru played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Exela Pharma Sciences
Exela Pharma Sciences, a fast-growing specialty pharmaceutical company, focuses on developing, manufacturing and marketing generic and proprietary injectable and sterile ophthalmic products that keep the healthcare provider and patient in mind. Our goal is to deliver high quality, affordable products that make a difference in peoples lives, and also meet the needs of the healthcare providers that treat them. Exela targets the development and manufacturing of generic and proprietary injectable and sterile ophthalmic products with high barriers to market entry, via an Abbreviated New Drug Approval or 505(b)(2) regulatory pathway. We develop products that enhance the patient or provider experience such as easing the burden of administration, providing an improved safety profile, faster drug perparation, or reduce drug waste. In other words, we strive to improve patient outcomes while reducing overall health care costs.

To learn more about Exela Pharma Sciences, visit http://www.exelapharma.com/

Contact:
Phanesh Koneru, Chief Executive Officer
888-451-4321

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved